Stockscreener 앱 받기
15.60
5.43%
-0.895
시간 외 거래:
15.50
-0.095
-0.61%
전일 마감가:
$16.49
열려 있는:
$15.68
하루 거래량:
164.75K
Relative Volume:
0.77
시가총액:
$2.02B
수익:
$65.48M
순이익/손실:
$-94.46M
주가수익비율:
-21.15
EPS:
-0.7375
순현금흐름:
$-71.18M
1주 성능:
-2.16%
1개월 성능:
-6.84%
6개월 성능:
-6.45%
1년 성능:
-1.67%
1일 변동 폭
$15.40
$15.68
1주일 범위
$15.40
$17.08
52주 변동 폭
$12.66
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
15.60 | 2.18B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Why Mesoblast (NASDAQ:MESO) Sees NASDAQ Composite Spotlight Now? - Kalkine Media
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast reaches 300-patient enrollment in back pain trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
Mesoblast (ASX:MSB): The Stem Cell Therapy Company on the Cusp of Commercial Reality - Kalkine
Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade - Kalkine
LWB1 Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LSX:A4004R) - TradingView
A4004R Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LS:A4004R) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (NASDAQ:MESO) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (GETTEX:LWB1) - TradingView
Mesoblast Ltd consensus and trial focus, shares watched on Nasdaq - Ad-hoc-news.de
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
MESO - Finviz
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Mesoblast LimitedDepositary Receipt (MESO) price target decreased by 14.96% to 15.33 - msn.com
Mesoblast completes enrollment in back pain therapy trial - Investing.com
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
Mesoblast H1 FY26 slides: first approved MSC product hits $49M - Investing.com
FARM 51 GROUP S.A.ZY -,1.XFRA: MWBMUHANDELSUNTERBRECHUNGTEIL 5 - aktiencheck.de
Mesoblast (NASDAQ: MESO) holders may resell 500,000 ADSs via warrants - Stock Titan
Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum - Stocks Down Under
Mesoblast announces board leadership changes as company evolves - Investing.com South Africa
Mesoblast Issues 5 Million Unquoted Warrants as Fee for US$50 Million Convertible Note Facility - TipRanks
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Insights: Mesoblast Ltd (ASX:MSB) - smallcaps.com.au
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):